<DOC>
	<DOCNO>NCT00124943</DOCNO>
	<brief_summary>The purpose study investigate use systemic intracoronary administration albumin-bound paclitaxel , ABI-007 , prevention reduction restenosis follow de novo stenting follow angioplasty in-stent restenosis .</brief_summary>
	<brief_title>Use Nanoparticle Paclitaxel ( ABI-007 ) Prevention In-Stent Restenosis</brief_title>
	<detailed_description>This study consist Phase I non-randomized dose escalation phase determine maximum tolerate dose randomized Phase II component ass preliminary efficacy . Nanoparticle paclitaxel administer intracoronary catheter follow either successful uncomplicated stenting de novo lesion native coronary artery follow successful uncomplicated balloon angioplasty instent restenosis ( ISR ) lesion .</detailed_description>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Male nonpregnant nonlactating female , ≥ 18 year age . Diagnosis angina pectoris unstable angina pectoris patient document silent ischemia . Left ventricular ejection fraction ≥30 % Patient undergone successful uncomplicated stenting 2 de novo lesion native coronary artery OR patient undergone successful uncomplicated balloon angioplasty 2 instent restenosis ( ISR ) lesion native coronary artery , . Thrombolysis In Myocardial Infarction ( TIMI ) 3 coronary flow poststenting de novo lesion post balloon angioplasty ISR lesion . No angiographic evidence thrombus postprocedure . Target vessel ≥2.5 mm diameter ( angiography ) . Each de novo lesion stented ≤ 25 mm single continuous stent . Each instent restenosis ( ISR ) lesion ≤ 25 mm length . There least 5 mm nondiseased vessel either side target lesion ( ) . By intravascular ultrasound ( IVUS ) , stent fully oppose minimum diameter 2.5 mm instent luminal area ≥ 5.0 mm^2 Patient guardian provide sign write informed consent participate study followup assessment use form approve local Institutional Review Board ( IRB ) /Ethics Committee investigative site . Target de novo lesion treat drugeluting stent Target ISR lesion require treatment balloon angioplasty Patient de novo lesion ISR lesion . If 2 lesion treat percutaneous coronary intervention ( PCI ) , anticipate additional lesion require treatment within 2 month . Previous PCI within precede two month . Intended surgical intervention within 6 month enrollment study . Unprotected leave main disease &gt; 50 % stenosis Malapposition , dissection , unmask significant narrowing inflow outflow area implant stent . Women pregnant woman child bear potential use adequate contraception Previous participation another study investigational drug device within past 30 day current enrollment clinical protocol investigational drug device trial . Patient life expectancy le 12 month factor make clinical and/or angiographic followup difficult Any significant medical condition , investigator 's opinion , may interfere patient 's optimal participation study Heart transplant candidate recipient Patient immunosuppressed HIV positive . Patient experience Q wave non Q wave myocardial infarction ( MI ) document total creatine kinase ( CK ) ≥2 time normal within precede 24 hour CK creatine kinaseMB fraction ( CKMB ) enzymes remain normal time procedure . Cardiogenic shock : sustain systolic blood pressure ( SBP ) less 80 mmHg , response fluid SBP le 100 mmHg vasopressor ( absence bradycardia ) Any individual may refuse blood transfusion Documented major gastrointestinal bleeding within 3 month The following lab value baseline exclusionary : Serum creatinine &gt; 2.5 mg/dl ; Platelet count &lt; 150,000 cells/mm^3 ; Absolute neutrophil count ( ANC ) &lt; 2000 cells/mm^3 ; Hemoglobin ( HGB ) &lt; 9 g/dl ; Total bilirubin &gt; 1.5 mg/dl ; Alanine Aminotransferase ( SGPT ) &gt; 2.5 x upper limit normal range ( ULN ) ; Aspartate Aminotransferase ( SGOT ) &gt; 2.5 x ULN ; Alkaline phosphatase &gt; 2.5 x ULN . Known allergy/hypersensitivity/contraindication study drug ; taxanes ; require study treatment : aspirin , clopidogrel bisulfate , stent material Preexisting peripheral neuropathy National Cancer Institute ( NCI ) Toxicity Grade &gt; 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Prevention Instent Restenosis</keyword>
</DOC>